Atorvastatin pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers for "atorvastatin pharmacokinetics"
Genetic Polymorphisms and Atorvastatin Pharmacokinetics
Atorvastatin pharmacokinetics are strongly influenced by genetic variations, particularly in the SLCO1B1, CYP3A4, CYP3A5, and UGT1A3 genes. Variants in SLCO1B1, such as c.521T>C, are associated with increased systemic exposure to atorvastatin and its metabolites, leading to higher area under the curve (AUC) values. Poor function SLCO1B1 genotypes can result in up to 145% higher atorvastatin AUC compared to normal function genotypes, while highly increased function genotypes show a 41% reduction in AUC. Similarly, CYP3A4 and CYP3A5 polymorphisms, such as CYP3A422 and CYP3A53, can increase atorvastatin exposure by reducing metabolic clearance. UGT1A3*2 and LPP rs1975991 variants also modulate atorvastatin and its metabolite levels, with LPP rs1975991 associated with reduced atorvastatin exposure. These genetic factors contribute to the variability in drug response and risk of side effects like myalgia Mykkänen2024Stillemans2021Park2022.
Role of Drug Transporters in Atorvastatin Disposition
Atorvastatin is a substrate for several transporters, including OATP1B1, OATP2B1, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP). OATP1B1 and OATP2B1 are key for hepatic uptake, with OATP2B1 particularly influencing intravenous atorvastatin clearance. In humanized rat models, expression of human OATP2B1 led to a 40% decrease in systemic exposure and a 57% increase in clearance after intravenous administration, highlighting its role in hepatic clearance. In muscle cells, variability in transporter gene expression can modulate atorvastatin levels, potentially impacting the risk of statin-related myotoxicities Wang2019Kinzi2024Hoste2025.
Impact of Drug-Drug Interactions on Atorvastatin Pharmacokinetics
Atorvastatin is extensively metabolized by CYP3A4, and its pharmacokinetics can be significantly altered by drugs that inhibit or induce this enzyme or its transporters. Co-administration with CYP3A4 inhibitors (such as certain antiretrovirals) can decrease atorvastatin clearance by up to 58%, resulting in a 180% increase in exposure. Conversely, CYP3A4 inducers can increase clearance by 78%, reducing exposure by 44%. These interactions are particularly relevant in populations with polypharmacy, such as people living with HIV Zhang2015Morse2019Courlet2020.
Physiologically Based Pharmacokinetic (PBPK) Modeling of Atorvastatin
PBPK models have been developed to predict atorvastatin pharmacokinetics and drug-drug interactions by incorporating data on metabolism, transport, and physiological variables. These models accurately describe the concentration-time profiles of atorvastatin and its metabolites under various scenarios, including the effects of delayed gastric emptying, acid-to-lactone conversion, and transporter/enzyme modulation. PBPK modeling is a valuable tool for optimizing dosing, assessing safety, and predicting responses in special populations or in the presence of interacting drugs Zhang2015Morse2019Reig-López2021.
Clinical Implications and Personalized Therapy
Population pharmacokinetic (PopPK) modeling in real-life settings shows that estimating atorvastatin clearance can help identify patients at risk of adverse effects, such as myalgia, and predict therapeutic efficacy. Lower clearance is associated with higher risk of muscle discomfort, while higher clearance correlates with better cholesterol-lowering effects. Incorporating genetic and clinical data into PK models supports personalized atorvastatin therapy, improving safety and effectiveness .
Conclusion
Atorvastatin pharmacokinetics are shaped by a complex interplay of genetic polymorphisms, transporter activity, metabolic enzymes, and drug-drug interactions. Advanced modeling approaches, such as PBPK and PopPK, enable better prediction of individual responses and support personalized dosing strategies to maximize efficacy and minimize adverse effects Mykkänen2024Zhang2015Wang2019+7 MORE.
Sources and full results
Most relevant research papers on this topic
Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP
Genetic variation in SLCO1B1, UGT1A3, LPP, and CYP3A4 affects atorvastatin pharmacokinetics, with LPP rs1975991 potentially reducing atorvastatin exposure.
Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites.
The developed PBPK model accurately predicts atorvastatin's pharmacokinetic profiles and drug-drug interactions, aiding in assessing its safety and efficacy in the clinic.
DOI